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Abstract
There is an urgent need for novel antibiotics as the current antibiotics are losing their value
due to increased resistance among clinically important bacteria. Sertraline, an on-marked
anti-depressive drug, has been shown to modify bacterial activity in vitro, including increas-
ing the susceptibility of Escherichia coli to antibiotics. The aim of the present study was to
investigate if the antimicrobial activity of sertraline could be documented under clinical set-
tings, hereunder if sertraline could potentiate the effect of tetracycline in treatment of an
experimentally induced ascending infection in poultry. A total of 40 chickens were divided in
four groups of 10 chickens each. All chickens were challenged with 4x103 colony forming
units (CFU) of a tetracycline resistant E. coli strain using a surgical infection model, and sub-
sequently treated with either high-dose sertraline, tetracycline, a combination hereof or
received no treatment. Seven days post challenge all birds were submitted to necropsy and
scored pathologically for lesions. The average lesion scores were significantly higher
(P<0.05) in the groups that were treated with high-dose sertraline or high-dose sertraline
combined with tetracycline. In conclusion high-dose treatments (four times the maximum
therapeutic dose for treating human depression) with sertraline as an adjuvant for treatment
of antibiotic resistant E. coli infections exacerbate the pathological outcome of infection in
chickens.
Introduction
The progressive incline in antimicrobial resistance of clinical important bacteria has led to an
increased focus of so-called non-antibiotics, which may be defined as medical compounds
whose primary indication for use is non-infectious diseases, but also processes antimicrobial
or antimicrobial helper compound effects [1]. Neurotropic medical compounds, such as
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phenothiazine and selective serotonin reuptake inhibitors (SSRIs) have been largely recognized
for their non-antibiotic properties [2–8]. Phenothiazine and derivatives hereof have shown
promising results for reversal of antimicrobial properties of multi-resistant Mycobacterium
strains [8–13], the causative agent of tuberculosis, which is a serious threat to human health
and highly prevalent in developing countries. In industrialized countries the emergence of
multi-resistant, clinically important Gram positive and Gram negative bacteria are likely to
constitute a health threat to humans and domestic animals [14–16]. Tetracycline is a valued
antibiotic in animal husbandry due to its broad-spectrum activities, low toxicity and several
oral-based formulations [17,18]. Tetracycline is also used in humane medicine, although the
use has decreased in the last decade, likely due to development of better antibiotics and due to
a dramatic increase in tetracycline resistant bacteria [17]. The increase in the prevalence of tet-
racycline resistance in clinically important bacteria in animals is a major problem as it forces
the use of other antibiotics for treatment of infectious disease in livestock production. Substi-
tuting tetracycline with other antibiotics primarily used for human infections, e.g. cephalos-
porines would favour selection of cephalosporin-resistant bacteria, which may be directly or
indirectly transferred to humans [19,20].
In vitro, sertraline, an SSRI compound, has shown synergy with tetracycline; hence
increased the sensitivity of tetracycline-resistant Escherichia coli strains to tetracycline [2,3,21].
If so, the combined treatment with sertraline and tetracycline may allow for the current use of
tetracycline even in infections caused by tetracycline resistant organisms in livestock produc-
tion, and even in human infections in which the infective organism has faced resistance to the
last line of antibiotics, such as colistin [22].
Therefore, the aim of the present study was to assess the effect of a combinational treatment
of sertraline and tetracycline in an experimentally induced infection caused by high-tetracy-
cline resistant E. coli in a chicken model of ascending bacterial infection.
Material and methods
Bacterial model organism
The strain of E. coli APEC_O2 (NCBI association nr. GCA_001620375.1) was used as chal-
lenge strain. The strain originates from a joint of a diseased chicken with arthritis [23]. The
strain carries two large plasmids, one being a virulence-associated plasmid [24] and the other
being an antimicrobial resistance plasmid, encoding resistance towards a number of antibiot-
ics and heavy metals, including tetracycline [25]. The virulence plasmid has been shown to
increase virulence in an avian air sac model [26] as well as contributing to enhanced killing of
embryos, growth in human urine and colonization of the murine kidney [27]. The present
study is the first to evaluate virulence of E. coli APEC_O2 in an avian ascending model.
Minimal inhibitory concentration (MIC) determinations and synergy
assessment
The minimum inhibitory concentration (MIC) of APEC_O2 for sertraline (Sigma-aldrich,
Denmark) and tetracycline (Sigma-aldrich, Denmark), respectively, were determined by serial
broth dilutions method [28].
Effect of sertraline on the MIC of tetracycline
Synergistic effect of sertraline on tetracycline activity against E. coli APEC O2 was evaluated by
checkerboard method with 96-well microtiter plates using MH broth, as described elsewhere
[29]. For each combination, the fractional inhibitory concentration (FIC) was calculated as the
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MIC of the tetracycline in combination with sertraline divided by the MIC of the tetracycline
alone and likewise for sertraline. The FIC indexes were derived from summation of individual
FICs. The efficacy of the combination effect was interpreted from the FIC index as follows:
synergism was defined as an FIC index 0.5; indifference as 0.5< FIC index 4; and antago-
nism as FIC index> 4 [28].
Experimental groups and housing
Forty brown layers (Bowan brown) were purchased from a commercial layer farm. At 42
weeks of age the layers were transferred from the farmer to the experimental housing unit at
University of Copenhagen. They were allowed three weeks of acclimatisation before the exper-
imental infections. During the acclimatisation period the birds were monitored for wellbeing,
normal avian behaviour and appetite. Birds were kept free range on deep litter in separate
floor pens (2.4 × 2.4 m) with unlimited access to nests, perches and dust baths. Water and
commercially layer feed was provided ad libitum in all groups throughout the experiment. All
procedures performed on the birds were approved and licensed by the Danish Animal Experi-
ments Inspectorate (license no. 2013-15-2934-00923).
Preparation of challenge inoculum
E. coli APEC_O2 was stored at—80˚C in Brain and Heart Infusion (BHI) broth (Oxoid,
Basingstoke, UK) in 15% (v/v) glycerol until needed. The day before inoculation the strain was
grown overnight in BHI broth. The overnight culture of the strain was diluted to 4×104 CFU,
and 0.1 ml of the diluted inoculum were aspirated in 1 ml syringes and kept on ice until
infection.
Oviduct infections, post challenge treatments and post mortem
assessment
Initially all birds were weighed, before the experiments were performed as described by Pors
et al. [30]. Briefly, each hen underwent laparotomy under general anaesthesia and received a
dose of 0.1 ml of approximately 4×104 CFU injected into the salpinx lumen. To avoid post-sur-
gical pain a semisynthetic opioid, buprenorphine (0.1 mg/kg), was administered to all hens in
all experimental groups during surgery, and repeated after 8 and 16 hours.
After completion of the oviduct infections, the forty layers were divided into four treatment
groups as shown in Table 1. The individual treatment dose was based on the body weight of
the chicken the day of experimental infection. Group one did not receive any further treat-
ment, while all chickens in group 2–4 were each treated once a day in four days, starting 48
hours post challenge. All treatments were given orally. Powder-form of either tetracycline
Table 1. Overview of experimental groups. Each group consisted of 10 commercially brown layers, 45
weeks of age.
Group Treatment Daily dose/ kg bodyweight (Day 2–5 after challenge)
1 None (infection control) None
2 Tetracycline 25 mg1
3 Sertraline 8 mg2
4 Tetracycline +sertraline 25 mg1 + 8 mg2
1 Corresponding to 50 mg Doxylin vet/ kg bodyweight,
2Corresponding to 16 mg Sertrone /kg bodyweight
https://doi.org/10.1371/journal.pone.0185914.t001
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(Doxylin Vet.) (group 2), sertraline (Sertrone) (group 3) or both tetracycline and sertraline
(group 4) were dissolved in 1 ml 0.9% NaCl and administered orally to each hen with a dis-
pensable 3 ml plastic transfer pipette.
All layers were weighed and euthanized by cervical dislocation seven days post challenge
(d.p.i.) and directly submitted to post mortem analysis, where lesions were scored according to
the scorings system outlined by Pors et al. [30]. Briefly, each organ system (ovary, peritoneum
and salpinx) was evaluated based on pre-defined criteria and assigned a score between 0 (no
macroscopically pathology) and 4 (extensive macroscopic pathology) for each criteria assessed.
The total cumulative score is the sum of scores for all evaluated organ systems in addition to
scores on spleen proliferation and lymphatic reaction. Two pathologists scored all lesions of all
chickens during the post mortem examination, and if any incongruence in scoring occurred, a
third pathologist also participated in the scoring process.
From each chicken, sampling from the bone marrow and the cranial and caudal salpinx
was done using cotton swabs and plated directly on agar plates (Oxoid, Basingstoke, UK) with
5% bovine blood. Re-isolation was considered positive if abundant growth in pure culture of
E. coli was obtained.
For determination of CFU/ gram salpinx tissue, approximately five centimetres of the mid-
dle part of salpinx (magnum) was removed aseptically, weighed off and added to 20 ml 0.9%
NaCl solution in a sterile Stomacher filterbag. The contents were homogenised in a stomacher
machine for 5 min, and 100 μl of the homogenate was used to make serial 10-fold dilutions in
0.9% NaCl. From each dilution 100 μl was placed on a Mu¨ller-Hinton (MH) plate supple-
mented with 10 mg/ml tetracycline, and distributed equally on the plate using sterile plastic
beads. All CFU dilutions were done in duplicate to ensure reproducibility.
Confirmation of re-isolated bacteria as being E. coli APEC O2 was done by PCR using
primers designed in the present study and described below.
E. coli APEC_O2 specific primer design
A draft genome sequence of E. coli APEC_O2 strain was used in this study for E. coli
APEC_O2 strain-specific primer design. pAPEC-O2-ColV and pAPEC-O2-R plasmids were
removed from the genome assembly, and the remaining contigs were aligned to 28 genetically-
related strains of E. coli representing sequence types ST135, ST452, ST-15, ST131, ST95,
ST140, ST127 and ST73 using progressive MAUVE [31]. Based on the alignment there were
168 regions found to be present specifically in E. coli APEC_O2. These regions were further
checked for similarity to other E. coli strains by BLAST in non-redundant nucleotide collection
of National Centre of Biotechnology Information (NCBI). Hits (n = 46) that were found to be
strictly located on a chromosome and/or representing phage sequences were further checked
for their similarity to other species in non-redundant nucleotide database, and for the presence
of their duplicates in APEC O2. This final step revealed 11 APEC_O2 strain-specific hits, one
of which of 217 bp representing phage-related antirepressor was used for primer design using
Primer3Plus [32] with the settings for qPCR within the program. Based on this five primer
pairs have been selected, and tested against 12 strains of genetically diverse collection of
APEC strains described by Ronco et al. [33]. Finally, one primer pair (Forward primer
ACCGTTTAGTGCTTCCCAAG; reverse primer ATTGCGACTTCTGTCATGC)with PCR condi-
tion including an initial denaturation of 5 min at 95˚C followed by 25 cycles of 30 sec at 95˚C,
30 sec annealing at 60˚C and 30 sec extension at 72˚C, and hereafter a finally 10 min of exten-
sion at 72˚C, yielding a 141 bp PCR product. The primers and PCR condition was proved to
be E. coli APEC_O2 strain-specific in the tested strain collection and was used in this study to
confirm re-isolated strains of E. coli as E. coli APEC_O2 in the present study.
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Histopathology and immunohistochemistry
For histopathological examination, pieces of the liver and kidney were fixed in 4% neutral
buffered formaldehyde solution for 48 h, subsequently trimmed, dehydrated and embedded in
paraffin wax prior to preparation of 3 to 5 μm thick sections, which were mounted on adhesive
slides (Super Frost/Plus; Menzel-Gla¨ser, Braunschweig, Germany).
Haematoxylin and eosin staining was performed according to a standard protocol [34].
An indirect immunostaining technique based on a specific E. coli rabbit monoclonal anti-
body (ab137967; Abcam plc, Cambridge, UK) according to the protocol described by Rossez
et al [35] was used for detections of E. coli in the tissue sections.
Statistical analysis
For the scoring of pathology, Kruskal–Wallis followed by Dunn’s Multiple Comparison test
was used for comparisons of lesion scores. CFU/per gram salpinx and the body weight changes
p.i., respectively, one-way ANOVA was used to compare group levels. Subsequently, Tukey’s
multiple comparison test compared group levels two-by-two for each of the two parameters.
All the statistical analysis was done with Graphpad Prism (Graphpad Software, Inc., La Jolla,
USA). P<0.05 was considered statistically significant.
Results
In vitro synergy assessment
For E. coli APEC_O2, MICs for tetracycline and sertraline were determined to 64 mg/L and
32 mg/L, respectively (Table 2). Synergy between tetracycline and sertraline as defined by
FIC 0.50, could be obtained for E. coli APEC_O2 at an exposure of 8 mg/L tetracycline com-
bined with 16 mg/L sertraline.
Pathological outcome of infection
The surgical procedure of infection was conducted in an uncomplicated manner for all chick-
ens. There were no mortality in any of the groups at day seven following challenge, and besides
a slight depression observed in all groups 12–24 hours after challenge, all chickens displayed
normal avian behaviour, and normal drinking and feeding activities, and the average weight
change per chicken did not differ significantly between groups (Fig 1).
At post mortem examination seven days post challenge, large variations in the pathological
outcome was observed (Fig 2). Overall, irrespective of post infection treatment gross macro-
scopic observation consisted of varying degrees of peritonitis, salpingitis and oophoritis. The
least severe pathology as defined by lowest lesions score were observed among chickens in the
Table 2. Minimal inhibitory concentration (MIC) of sertraline and tetracycline alone or combined. For
each combination exposure on sertraline and tetracycline, the fractional inhibitory concentration index (FICI)
is stated.
MIC FICI
Tetracycline (μg/ml) Sertraline (μg/ml)
0 32 -
64 0 -
32 0.25 0.96
16 8 0.50
4 16 0.56
https://doi.org/10.1371/journal.pone.0185914.t002
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untreated control group, although the median score did not differ significantly from the
median lesion score of chickens in the tetracycline-treated group. For the untreated group of
chickens, 6/10 did not demonstrate any pathology at all (lesion score 0), while 5/10 chickens in
the tetracycline-treated group all had lesion score of 5 or lower.
When compared to the untreated and tetracycline-treated groups, the pathology observed
in the remaining groups (sertraline and sertraline/tetracycline) was considerably more severe
and productive/suppurative, and only a single chicken had a lesion score below 10 in the ser-
traline-treated group, and for the sertraline/tetracycline treatment group, 3/10 chickens had a
lesion score greater than 20. The median lesion score in both the sertraline and sertraline/ tet-
racycline treatment group were significantly higher than the control group (P< 0.011 and
P<0.014, respectively).
Fig 1. Weight changes during infection. Percent weight change seven days after infection compared to before
infection per chicken in the different treatment groups.
https://doi.org/10.1371/journal.pone.0185914.g001
Sertraline and bacterial infections
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Histopathology and immunohistochemistry
Similar to the macroscopic variations observed, the histopathological observations also ranged
from no histopathological findings to severe vacuolisation of the hepatic cells in the different
groups (Fig 3). Severe vacuolisation of the hepatic cells were solely found in liver sections from
chickens in the sertraline- or sertraline/tetracycline groups. No histopathological findings
were observed in the kidney sections, irrespectively of treatment groups. Positive staining for
E. coli was not observed in any of the tissue samples.
Fig 2. Lesion scores. Median lesion score per chicken in the different treatment groups. Vertical bars indicate
standard deviation, and asterisk indicated statistical difference in lesion score compared to the non-treated control
group.
https://doi.org/10.1371/journal.pone.0185914.g002
Sertraline and bacterial infections
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CFU of the salpinx
For all chickens, CFU of E. coli APEC_O2 in approximately 20 gram of the salpinx was deter-
mined. There was no difference between the average CFU/g salpinx per chicken between
groups (p = 0.171) (Fig 4).
Fig 3. Liver histology. a) Liver section from a chicken in the control group (not receiving any treatment after
challenge with E. coli APEC_O2). Notice the normal and regular hepatocytes; b) Liver section from a chicken
in the sertraline-treated group. Notice the major vacuolization of the hepatocytes. Each of the large images is
at 20X magnification, insert in the corners are from the same image, but at 40X magnification.
https://doi.org/10.1371/journal.pone.0185914.g003
Sertraline and bacterial infections
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The weight of each chicken was measured before and seven days after challenge. There
were no statistical differences in the average weight changes per chicken between groups
(Fig 1).
Discussion
In humans, urinary tract infections (UTI) due to E. coli are one of the most common reasons
for antibiotic treatment in clinical practise [36]. Emergence of multi-resistant E. coli will conse-
quently have major impact of treatment success of UTI in human medicine. Similar, in poultry
E. coli is the most frequent cause of ascending infections, and accumulating evidence suggest
that the clones of E. coli causing ascending infections in poultry are highly similar to clones of
E. coli causing UTI in human [23,37]. In the present study we have assessed the potential of
Fig 4. Colony-forming units (CFU). CFU per gram salpinx in the different treatment groups. Vertical bars indicate
the standard deviation.
https://doi.org/10.1371/journal.pone.0185914.g004
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sertraline as antimicrobial or as an antimicrobial helper compound in the treatment of experi-
mental ascending E. coli infections in poultry.
In the study, the strain E. coli APEC_O2 was used as challenge strain. The strain was chosen
because it is a tetracycline resistant avian pathogenic E. coli and because it has been shown to
possess a plasmid enhancing survival in human urine and increasing colonization of the
murine kidney [27]. The strain has, however, never been used to experimentally infect the sal-
pinx of poultry, therefore the virulence potential in this aspect was unknown prior to the pres-
ent study. In the infection control group (Group 1) only 4/10 chickens had recognisable
macroscopic pathology, while the remaining six chickens in the group showed no signs of
gross pathology. Out of these six macroscopically unaffected chickens, E. coli APEC_O2 could
not be re-isolated from the tissue either (Fig 3). The host-related factors resulting in varying
susceptibility is well-documented, although it could be argued if the infection dose used was
too low [30]. Ideally, 10/10 chickens in the untreated group would had shown gross pathology
consistent with an ascending E. coli infection. However, previous studies have documented
that host-related factors, the infection dose and strain-related characteristics are important
parameters for infection outcome [38]. In a recent study, applying the same method, but using
another strain of E. coli as challenge, a 100% mortality two days post challenge was observed
when applying a dose of 5x105 CFU [39]. To optimize the chances for full survival of all chick-
ens in all groups, while still ensuring an infection to be established in at least part of the chick-
ens, the dose was set two log units lower than in the previously mentioned study.
As E. coli APEC_O2 is tetracycline resistant, it was not surprising that the pathology in the
tetracycline-treated group was highly similar to the observations done in the un-treated con-
trol group. The CFU per gram salpinx were also similar with the counts in the control group,
although two chickens had CFU counts significantly higher than for any of the chickens in the
control group (Fig 4), indicating clearly that E. coli APEC_O2 is not inhibited by tetracycline,
unless administered in concentrations eight times higher than the cut-off value of tetracycline
sensitivity of E. coli as defined by EUCAST[40] (Table 2).
In contrast to all other groups, all but one chicken in the tetracycline-treated group, actually
had gained weight in the week following infection (Fig 1). If this is due to ease of infection, and
consequently greater appetite, or a better feed conversion rate when tetracycline is adminis-
tered as suggested by several studies [41,42] is unknown as all groups were feed ad libitum
with no records on actual feed intake, but anorexia/decrease in appetite was not observed in
any of the groups during the trial.
At seven days post challenge, the bone-marrow of all chickens from all groups was culture
negative, indicative of the lack of a septic/bacteraemic condition. In agreement E. coli was not
detected in any of the histopathological slides. The severity of the macroscopic pathology
observed for chickens in sertraline and sertraline/tetracycline treated groups was highly simi-
lar, and more pronounced than in the un- or tetracycline- treated groups (Fig 1). The infec-
tions were considerably more productive and more extensive cases of peritonitis involving the
entire peritoneal cavity were observed. The histopathology revealed the chickens in these
groups also had marked vacuolisation of the hepatic cells (Fig 3), a finding previously associ-
ated with infectious diseases in avian species [43]. In contrast, the level of CFU in salpinx was
statistically indifferent from counts in the control group although there was a tendency to
higher counts among chickens in the sertraline/tetracycline treated group (Fig 4). Based on the
in vitro synergy assessment assay, it was evident that a relative high concentration of sertraline
is needed to reduce the tetracycline resistance of E. coli APEC_O2 to 8 mg/L tetracycline, the
epidemiological cut-off for resistance [40]. As sertraline is known to have a low toxicity [44],
and due to the in vitro observations (Table 2), a daily dose of 8 mg sertraline/kg body mass
Sertraline and bacterial infections
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chicken was considered as a relevant experimental dose, which is approximately 2.5 times the
concentration used to treat severe clinical depression in human medicine [45].
The more severe outcome of infection in the sertraline/tetracycline group was unexpected,
as it was hypothesized to significantly improve/combat the infection. An explanation for the
unexpected discrepancy of the pathology and CFU counts when compared to control group
was sought for in the literature. As to the authors knowledge this is the first time sertraline
treatment in chickens in an infectious model has been described. In behavioural (non-infec-
tious) avian studies, exposure of SSRI compounds in concentrations from 5.0 mg/L [46] to 25
mg/L [47] have been published with no reports on observed pathology/toxically when SSRIs
are used in poultry. Neither did the histopathological examination in the present study show
any signs of increased toxicities. There were, however, signs of exacerbated infection (liver
vacuolisation), indicating the bacterial infection rather than the compound of sertraline per see
worsened the outcome. These observations may lead to the tentative conclusion that the sertra-
line compromise the innate immune system of the chickens. In humans, SSRIs has been docu-
mented to suppress lymphocyte proliferation, cytokine secretion and viability in vitro, although
the mechanism behind SSRI-induced immunological effects remains to be elucidated [48]. The
finding that SSRIs suppress unwanted immune reactions has been demonstrated in animal
models of autoimmune disorders, such as rheumatoid arthritis [49] and multiple sclerosis [50].
Furthermore, a beneficial effect of SSRIs in the treatment of lymphoma has been proposed, pre-
sumably attributed to both a direct suppressive effect on the malignant cells and a stimulatory
effect on anti-cancer immunity [51,52]. Finally, recent evidence showed an effect of fluoxetine,
another SSRI compound, on neutrophil adhesion and recruitment to inflammatory sites, dem-
onstrating that not only cellular but also innate immunity is impacted by SSRIs [53].
Only few studies have investigated the interaction of SSRI and bacterial infection, experi-
mentally induced [54] or clinical observations [55]. For the latter, a recent study documented
that there is an increased risk of acquiring a Clostridium difficile infection when taking daily
doses of SSRI [56,57], despite that it is generally assumed that the required doses for immuno-
suppression has been suggested to be higher than those used to treat depression [48]. In con-
trast, relatively low concentrations (0.1–1 μM) of a SSRI compound, fluoxetine, have been
found to stimulate T cell proliferation [58].
The avian immune system resembles that of mammals since both evolved from a common
reptilian ancestor and have inherited many commonalities [59]. They have also developed a
number of different strategies that are unique to birds. The lymphoid organs plays a major role
in avian immunity, with the bursa of Fabricius (site of B-cell origin) and the thymus (site of T-
cell origin) are considered primary lymphoid organs [60]. Since T-cells are suggested to be par-
ticular sensitive to high-doses sertraline [61], it may be speculated that avian species are partic-
ular susceptible to SSRI-induced immunosuppression.
In conclusion, although sertraline has a synergic effect with tetracycline in vitro, combina-
tional treatment with sertraline and tetracycline significantly worsen the pathological outcome
of infection in an experimental bacterial infection model. These findings may be explained by
an immunosuppressive effect of sertraline when applied in doses four times that of clinical
doses recommended for treatment of central nervous system disorders in man.
A possible beneficial effect of lower doses of sertraline in combination with tetracycline
treatment of tetracycline resistant E. coli infections requires future studies to answer.
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